Why Inovio Stock Is Crashing Today

235
52
Favorite

Why Inovio Stock Is Crashing Today

Motley Fool 2021-04-23

The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate. What happened Shares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

235

Report

Comment（52）

JaydenSee
·2021-04-25
Pls like and comments
Reply
2
Report
Fold Replies
- 3piglet:
  Same
  2021-04-27
  Reply
  Report
- JaydenSee:
  thanks
  2021-04-26
  Reply
  Report
- EV8:
  ??
  2021-04-25
  Reply
  Report
View more 1 comments
Goldox
·2021-04-25
Gg
Reply
Like
Report
黑豹钻石拳
·2021-04-25
[微笑]
Reply
3
Report
Fold Replies
- The Knight:
  Buy Or not
  2021-04-27
  Reply
  Report
- 黑豹钻石拳:
  [Speechless]
  2021-04-25
  Reply
  Report
- 黑豹钻石拳:
  [Speechless]
  2021-04-25
  Reply
  Report
View more 2 comments
S土豪熊貓G
·2021-04-25
Pls comments and likes. Thanks!
Reply
3
Report
Fold Replies
- S土豪熊貓G:
  Thanks Huat99
  2021-04-25
  Reply
  Report
- Huat99:
  okok
  2021-04-25
  Reply
  Report
AndyQuak
·2021-04-25
Comment thanks
Reply
2
Report
Fold Replies
- JBSIEW:
  Good day.
  2021-04-25
  Reply
  Report
JBSIEW
·2021-04-25
Up fast, down also fast. Even Pfizer's price also not up more than 30%.
Reply
3
Report
Fold Replies
- AndyQuak:
  comment thanks
  2021-04-25
  Reply
  Report
BeHappy
·2021-04-25
I have no idea
Reply
3
Report
Jusdidas
·2021-04-25
Please like and comment!
Reply
2
Report
Fold Replies
- Sandy92:
  done. please like and comment back
  2021-04-25
  Reply
  Report
Lim89
·2021-04-25
Why not
Reply
2
Report
knowplay
·2021-04-24
Good
Reply
Like
Report
Poisonz
·2021-04-24
Lol
Reply
Like
Report
Crip
·2021-04-24
Joke
Reply
6
Report
Fold Replies
- hellotomato:
  :/
  2021-04-24
  Reply
  Report
DogeFather69
·2021-04-24
Wtf
Reply
2
Report
mr_tig3r
·2021-04-24
Ok
Reply
3
Report
xuanlin
·2021-04-24
Comment pls
Reply
1
Report
Fold Replies
- Qarah:
  Done!
  2021-04-25
  Reply
  Report
justinC
·2021-04-24
Like and commment please
Reply
2
Report
Fold Replies
- justinC:
  ple
  2021-04-24
  Reply
  Report
dahae
·2021-04-24
comment pls
Reply
3
Report
Fold Replies
- dahae:
  .
  2021-04-25
  Reply
  Report
- dahae:
  .
  2021-04-25
  Reply
  Report
- pandajojo:
  Like n comment
  2021-04-25
  Reply
  Report
Ivylow
·2021-04-24
?
Reply
1
Report
Ivylow
·2021-04-24
$
Reply
Like
Report
Ivylow
·2021-04-24
?
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1122047796?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-23 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122047796","market":"us","top_or_hot":-1,"title":"Why Inovio Stock Is Crashing Today","media":" Motley Fool ","content":"<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INO","symbol_name":"伊诺维奥制药","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","article_id":"1122047796","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","pubTimestamp":1619190353,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"INO":"伊诺维奥制药"},"translate_title":"为什么Inovio股票今天暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":0.9},"content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":375138361,"gmtCreate":1619314440653,"gmtModify":1704722289153,"author":{"id":"3571546243427161","authorId":"3571546243427161","name":"JaydenSee","avatar":"https://static.tigerbbs.com/f81b1d1b9ef76e9028b0f68e5a5d3553","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3571546243427161","authorIdStr":"3571546243427161"},"htmlText":"Pls like and comments&nbsp;","listText":"Pls like and comments&nbsp;","text":"Pls like and comments","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/375138361","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4140507,"gmtCreate":1619452821402,"gmtModify":1680785705404,"authorId":3573385929982547,"author":{"id":3573385929982547,"idStr":"3573385929982547","authorId":3573385929982547,"name":"3piglet","avatar":"https://static.tigerbbs.com/6d75c13e0fb682bf1746d89879850b9e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":0,"prevId":0,"content":"Same","text":"Same","html":"Same"},{"id":4135857,"gmtCreate":1619414609297,"gmtModify":1680785633377,"authorId":3571546243427161,"author":{"id":3571546243427161,"idStr":"3571546243427161","authorId":3571546243427161,"name":"JaydenSee","avatar":"https://static.tigerbbs.com/f81b1d1b9ef76e9028b0f68e5a5d3553","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":4130172,"prevId":0,"content":"thanks","text":"thanks","html":"thanks"},{"id":4130172,"gmtCreate":1619356532270,"gmtModify":1680785541880,"authorId":3576472032670521,"author":{"id":3576472032670521,"idStr":"3576472032670521","authorId":3576472032670521,"name":"EV8","avatar":"https://community-static.tradeup.com/news/49db5086746d5ad4581b298b77a14995","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.50%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"},{"id":4125671,"gmtCreate":1619314896606,"gmtModify":1680785469089,"authorId":3576484544353713,"author":{"id":3576484544353713,"idStr":"3576484544353713","authorId":3576484544353713,"name":"Milkgonebad","avatar":"https://static.tigerbbs.com/13596b6d0ccd5ec5f1323ca987d7ae85","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.39%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375138361,"type":1,"supId":0,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"}],"langContent":"EN"},{"id":375375483,"gmtCreate":1619312743342,"gmtModify":1704722253676,"author":{"id":"3574248655626938","authorId":"3574248655626938","name":"Goldox","avatar":"https://static.tigerbbs.com/863110a9408a00f21e04f570ea1c03f2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574248655626938","authorIdStr":"3574248655626938"},"htmlText":"Gg","listText":"Gg","text":"Gg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375375483","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375347083,"gmtCreate":1619312338142,"gmtModify":1704722241890,"author":{"id":"3570880740385047","authorId":"3570880740385047","name":"黑豹钻石拳","avatar":"https://community-static.tradeup.com/news/b985aa64c924e2e2db014d0b48b16d96","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3570880740385047","authorIdStr":"3570880740385047"},"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/375347083","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4142837,"gmtCreate":1619480287832,"gmtModify":1680785733046,"authorId":3570437600969291,"author":{"id":3570437600969291,"idStr":"3570437600969291","authorId":3570437600969291,"name":"The Knight","avatar":"https://static.tigerbbs.com/75dcd9b9c7a6f69cb6e3d99df5c339df","vip":1,"currentWearingBadge":{"badgeId":"4e86300037264823b9bb00ff44fc0f19-5","templateUuid":"4e86300037264823b9bb00ff44fc0f19","name":"Live trading challenger","description":"for 10 months","bigImgUrl":"https://community-static.tradeup.com/news/50836b6acaa4041c6613cc97eeeb364b","smallImgUrl":"https://community-static.tradeup.com/news/a6b8bf4481e36ae8a863eae5098461e6","grayImgUrl":"https://community-static.tradeup.com/news/91c1c1e4d3607b46e414ab97cc6dd982","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.03","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5600},"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.23","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":0,"prevId":0,"content":"Buy Or not","text":"Buy Or not","html":"Buy Or not"},{"id":4127429,"gmtCreate":1619327148758,"gmtModify":1680785491184,"authorId":3570880740385047,"author":{"id":3570880740385047,"idStr":"3570880740385047","authorId":3570880740385047,"name":"黑豹钻石拳","avatar":"https://community-static.tradeup.com/news/b985aa64c924e2e2db014d0b48b16d96","vip":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.24","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.23","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":4127033,"prevId":0,"content":"[Speechless]","text":"[Speechless]","html":"[Speechless]"},{"id":4127430,"gmtCreate":1619327156315,"gmtModify":1680785490386,"authorId":3570880740385047,"author":{"id":3570880740385047,"idStr":"3570880740385047","authorId":3570880740385047,"name":"黑豹钻石拳","avatar":"https://community-static.tradeup.com/news/b985aa64c924e2e2db014d0b48b16d96","vip":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.24","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.23","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":4126678,"prevId":0,"content":"[Speechless]","text":"[Speechless]","html":"[Speechless]"},{"id":4126678,"gmtCreate":1619321450120,"gmtModify":1680785489116,"authorId":3570437600969291,"author":{"id":3570437600969291,"idStr":"3570437600969291","authorId":3570437600969291,"name":"The Knight","avatar":"https://static.tigerbbs.com/75dcd9b9c7a6f69cb6e3d99df5c339df","vip":1,"currentWearingBadge":{"badgeId":"4e86300037264823b9bb00ff44fc0f19-5","templateUuid":"4e86300037264823b9bb00ff44fc0f19","name":"Live trading challenger","description":"for 10 months","bigImgUrl":"https://community-static.tradeup.com/news/50836b6acaa4041c6613cc97eeeb364b","smallImgUrl":"https://community-static.tradeup.com/news/a6b8bf4481e36ae8a863eae5098461e6","grayImgUrl":"https://community-static.tradeup.com/news/91c1c1e4d3607b46e414ab97cc6dd982","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.03","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5600},"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.23","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":0,"prevId":0,"content":"??? Why??","text":"??? Why??","html":"??? Why??"},{"id":4127033,"gmtCreate":1619323378987,"gmtModify":1680785485352,"authorId":3571138623117037,"author":{"id":3571138623117037,"idStr":"3571138623117037","authorId":3571138623117037,"name":"Werkohderkoh","avatar":"https://static.tigerbbs.com/15f00b0aef0edf959d4cceebd1513729","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375347083,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"CN"},{"id":375354935,"gmtCreate":1619311665327,"gmtModify":1704722226990,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578811676095048","authorIdStr":"3578811676095048"},"htmlText":"Pls comments and likes. Thanks!","listText":"Pls comments and likes. Thanks!","text":"Pls comments and likes. Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/375354935","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4126666,"gmtCreate":1619321327058,"gmtModify":1680785486119,"authorId":3578811676095048,"author":{"id":3578811676095048,"idStr":"3578811676095048","authorId":3578811676095048,"name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375354935,"type":1,"supId":4125101,"prevId":0,"content":"Thanks Huat99","text":"Thanks Huat99","html":"Thanks Huat99"},{"id":4125101,"gmtCreate":1619312169817,"gmtModify":1680785464053,"authorId":3555376654101817,"author":{"id":3555376654101817,"idStr":"3555376654101817","authorId":3555376654101817,"name":"Huat99","avatar":"https://static.tigerbbs.com/2c30eb3331cf3fbbc42818b462456369","vip":1,"currentWearingBadge":{"badgeId":"1f541396f99840fb977d0ab0ce343c94-1","templateUuid":"1f541396f99840fb977d0ab0ce343c94","name":"Weekly Top Contributor","description":"Contributors with best Editor's Picks every week","bigImgUrl":"https://static.tigerbbs.com/271475ceaf67d40016c8cfa16c08c8b3","smallImgUrl":"https://static.tigerbbs.com/5a6336061b9ba82ba9177c7ec476f5f2","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":3,"allocatedDate":"2022.09.26","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2004},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375354935,"type":1,"supId":0,"prevId":0,"content":"okok","text":"okok","html":"okok"}],"langContent":"EN"},{"id":375382126,"gmtCreate":1619308925265,"gmtModify":1704722184594,"author":{"id":"3576709266160370","authorId":"3576709266160370","name":"AndyQuak","avatar":"https://static.tigerbbs.com/bd9f635e190b833549d9282c6e3e2f59","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576709266160370","authorIdStr":"3576709266160370"},"htmlText":"Comment thanks&nbsp;","listText":"Comment thanks&nbsp;","text":"Comment thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/375382126","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124627,"gmtCreate":1619309853233,"gmtModify":1680785456042,"authorId":3563244604368605,"author":{"id":3563244604368605,"idStr":"3563244604368605","authorId":3563244604368605,"name":"JBSIEW","avatar":"https://static.tigerbbs.com/98de4f8fefba82ae441dde7b51ef936d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375382126,"type":1,"supId":0,"prevId":0,"content":"Good day.","text":"Good day.","html":"Good day."}],"langContent":"EN"},{"id":375314661,"gmtCreate":1619307958953,"gmtModify":1704722173760,"author":{"id":"3563244604368605","authorId":"3563244604368605","name":"JBSIEW","avatar":"https://static.tigerbbs.com/98de4f8fefba82ae441dde7b51ef936d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3563244604368605","authorIdStr":"3563244604368605"},"htmlText":"Up fast, down also fast. Even Pfizer's price also not up more than 30%.","listText":"Up fast, down also fast. Even Pfizer's price also not up more than 30%.","text":"Up fast, down also fast. Even Pfizer's price also not up more than 30%.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/375314661","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124510,"gmtCreate":1619308936260,"gmtModify":1680785454424,"authorId":3576709266160370,"author":{"id":3576709266160370,"idStr":"3576709266160370","authorId":3576709266160370,"name":"AndyQuak","avatar":"https://static.tigerbbs.com/bd9f635e190b833549d9282c6e3e2f59","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375314661,"type":1,"supId":0,"prevId":0,"content":"comment thanks","text":"comment thanks","html":"comment thanks"}],"langContent":"EN"},{"id":375334046,"gmtCreate":1619306974185,"gmtModify":1704722159501,"author":{"id":"3580416813447115","authorId":"3580416813447115","name":"BeHappy","avatar":"https://static.tigerbbs.com/de3a06dde5f6ecf00082e1f076b52587","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3580416813447115","authorIdStr":"3580416813447115"},"htmlText":"I have no idea","listText":"I have no idea","text":"I have no idea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375334046","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375303967,"gmtCreate":1619302905259,"gmtModify":1704722125522,"author":{"id":"3579917251051668","authorId":"3579917251051668","name":"Jusdidas","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3579917251051668","authorIdStr":"3579917251051668"},"htmlText":"Please like and comment!","listText":"Please like and comment!","text":"Please like and comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/375303967","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124332,"gmtCreate":1619307499786,"gmtModify":1680785443167,"authorId":3563504647645776,"author":{"id":3563504647645776,"idStr":"3563504647645776","authorId":3563504647645776,"name":"Sandy92","avatar":"https://static.tigerbbs.com/9f86355f6dbed4dfca34d989df1a36e1","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375303967,"type":1,"supId":0,"prevId":0,"content":"done. please like and comment back","text":"done. please like and comment back","html":"done. please like and comment back"}],"langContent":"EN"},{"id":375977682,"gmtCreate":1619302248446,"gmtModify":1704722121961,"author":{"id":"3527303552443900","authorId":"3527303552443900","name":"Lim89","avatar":"https://static.tigerbbs.com/f21e4020ff962f4d66f99662b584ec1c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3527303552443900","authorIdStr":"3527303552443900"},"htmlText":"Why not","listText":"Why not","text":"Why not","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375977682","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375987580,"gmtCreate":1619277679440,"gmtModify":1704722059951,"author":{"id":"3582195961698597","authorId":"3582195961698597","name":"knowplay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582195961698597","authorIdStr":"3582195961698597"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375987580","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375987840,"gmtCreate":1619277598680,"gmtModify":1704722059627,"author":{"id":"3581834128004381","authorId":"3581834128004381","name":"Poisonz","avatar":"https://static.tigerbbs.com/5e0dd20af13212be3d544bc41039e0fe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581834128004381","authorIdStr":"3581834128004381"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375987840","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375937133,"gmtCreate":1619274981622,"gmtModify":1704722034704,"author":{"id":"3580169073488033","authorId":"3580169073488033","name":"Crip","avatar":"https://static.itradeup.com/news/ebea0e00f72e4c4d5767a18871c0022e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580169073488033","authorIdStr":"3580169073488033"},"htmlText":"Joke","listText":"Joke","text":"Joke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/375937133","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4123362,"gmtCreate":1619279671648,"gmtModify":1680785434679,"authorId":3576561701314627,"author":{"id":3576561701314627,"idStr":"3576561701314627","authorId":3576561701314627,"name":"hellotomato","avatar":"https://static.tigerbbs.com/5a5be72959c7fb86f0212f7bbbbfbc84","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375937133,"type":1,"supId":0,"prevId":0,"content":":/","text":":/","html":":/"}],"langContent":"EN"},{"id":375990151,"gmtCreate":1619271608673,"gmtModify":1704722008191,"author":{"id":"3562800806331755","authorId":"3562800806331755","name":"DogeFather69","avatar":"https://static.tigerbbs.com/012eed43a063aef772d43c0a45a463d9","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":1,"crmLevelSwitch":0,"idStr":"3562800806331755","authorIdStr":"3562800806331755"},"htmlText":"Wtf","listText":"Wtf","text":"Wtf","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375990151","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375908002,"gmtCreate":1619270411606,"gmtModify":1704721999542,"author":{"id":"3579092031958753","authorId":"3579092031958753","name":"mr_tig3r","avatar":"https://static.tigerbbs.com/333e3ca9288379f6071ce74d34fdb629","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579092031958753","authorIdStr":"3579092031958753"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375908002","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375900315,"gmtCreate":1619269359637,"gmtModify":1704721993809,"author":{"id":"3575152506937716","authorId":"3575152506937716","name":"xuanlin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575152506937716","authorIdStr":"3575152506937716"},"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/375900315","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4124929,"gmtCreate":1619311317952,"gmtModify":1680785458311,"authorId":3570439473038184,"author":{"id":3570439473038184,"idStr":"3570439473038184","authorId":3570439473038184,"name":"Qarah","avatar":"https://static.tigerbbs.com/48285a44928a897dd5f255c626d5e9e1","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375900315,"type":1,"supId":0,"prevId":0,"content":"Done!","text":"Done!","html":"Done!"}],"langContent":"EN"},{"id":375045776,"gmtCreate":1619266813195,"gmtModify":1704721977311,"author":{"id":"3580980349710552","authorId":"3580980349710552","name":"justinC","avatar":"https://static.tigerbbs.com/b1df8f1b7bfcecfea836a18bee080563","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580980349710552","authorIdStr":"3580980349710552"},"htmlText":"Like and commment please","listText":"Like and commment please","text":"Like and commment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/375045776","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4122481,"gmtCreate":1619266846808,"gmtModify":1680785425607,"authorId":3580980349710552,"author":{"id":3580980349710552,"idStr":"3580980349710552","authorId":3580980349710552,"name":"justinC","avatar":"https://static.tigerbbs.com/b1df8f1b7bfcecfea836a18bee080563","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375045776,"type":1,"supId":0,"prevId":0,"content":"<u>ple</u>","text":"<u>ple</u>","html":"<u>ple</u>"}],"langContent":"EN"},{"id":375051553,"gmtCreate":1619264281572,"gmtModify":1704721957578,"author":{"id":"3560092322694803","authorId":"3560092322694803","name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3560092322694803","authorIdStr":"3560092322694803"},"htmlText":"comment pls&nbsp;","listText":"comment pls&nbsp;","text":"comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/375051553","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4129346,"gmtCreate":1619346997672,"gmtModify":1680785528858,"authorId":3560092322694803,"author":{"id":3560092322694803,"idStr":"3560092322694803","authorId":3560092322694803,"name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375051553,"type":1,"supId":4123799,"prevId":0,"content":".","text":".","html":"."},{"id":4129376,"gmtCreate":1619347356470,"gmtModify":1680785523296,"authorId":3560092322694803,"author":{"id":3560092322694803,"idStr":"3560092322694803","authorId":3560092322694803,"name":"dahae","avatar":"https://static.tigerbbs.com/137beae1f6048901843924ba46796740","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375051553,"type":1,"supId":4123799,"prevId":0,"content":".","text":".","html":"."},{"id":4123799,"gmtCreate":1619301058896,"gmtModify":1680785442500,"authorId":3578965435978206,"author":{"id":3578965435978206,"idStr":"3578965435978206","authorId":3578965435978206,"name":"pandajojo","avatar":"https://static.tigerbbs.com/7efe44a2514d987c5a8b342b85d6f229","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":375051553,"type":1,"supId":0,"prevId":0,"content":"Like n <u>comment</u>","text":"Like n <u>comment</u>","html":"Like n <u>comment</u>"}],"langContent":"EN"},{"id":375064086,"gmtCreate":1619261087145,"gmtModify":1704721935359,"author":{"id":"3582161778784599","authorId":"3582161778784599","name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582161778784599","authorIdStr":"3582161778784599"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375064086","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375065464,"gmtCreate":1619261062558,"gmtModify":1704721935036,"author":{"id":"3582161778784599","authorId":"3582161778784599","name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582161778784599","authorIdStr":"3582161778784599"},"htmlText":"$","listText":"$","text":"$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375065464","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":375065642,"gmtCreate":1619261038586,"gmtModify":1704721934712,"author":{"id":"3582161778784599","authorId":"3582161778784599","name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582161778784599","authorIdStr":"3582161778784599"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/375065642","repostId":1122047796,"repostType":4,"repost":{"id":"1122047796","kind":"news","pubTimestamp":1619190353,"share":"https://ttm.financial/m/news/1122047796?lang=&edition=fundamental","pubTime":"2021-04-23 23:05","market":"us","language":"en","title":"Why Inovio Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1122047796","media":" Motley Fool ","summary":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happe","content":"<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.</p>\n<p><b>What happened</b></p>\n<p>Shares of&nbsp;<b>Inovio Pharmaceuticals</b>&nbsp;(NASDAQ:INO)&nbsp;were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.</p>\n<p><b>So what</b></p>\n<p>The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the&nbsp;biotech stock&nbsp;after this news isn't surprising.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27c0ce391c793e938d8e0e7d27f95a40\" tg-width=\"2000\" tg-height=\"1500\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>Why did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"</p>\n<p>That kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.</p>\n<p>The U.S. already has supply deals in place with&nbsp;<b>Pfizer</b>,<b>Moderna</b>, and&nbsp;<b>Johnson &amp; Johnson</b>&nbsp;for more than enough doses to fully vaccinate every American. COVID-19 vaccines from&nbsp;<b>AstraZeneca</b>&nbsp;and&nbsp;<b>Novavax</b>could soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.</p>\n<p><b>Now what</b></p>\n<p>The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Inovio Stock Is Crashing Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Inovio Stock Is Crashing Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/><strong> Motley Fool </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/04/23/why-inovio-stock-is-crashing-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122047796","content_text":"The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate.\nWhat happened\nShares of Inovio Pharmaceuticals (NASDAQ:INO) were crashing 26.8% as of 11:05 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.\nSo what\nThe loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.\nIMAGE SOURCE: GETTY IMAGES.\nWhy did the Defense Department pull the plug on funding the late-stage study? Inovio said that the department's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) told the company: \"The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines. This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products.\"\nThat kind of sounds like the old line used when couples break up: \"It's not you, it's me.\" However, in this case, it makes sense.\nThe U.S. already has supply deals in place with Pfizer,Moderna, and Johnson & Johnson for more than enough doses to fully vaccinate every American. COVID-19 vaccines from AstraZeneca and Novavaxcould soon win Emergency Use Authorizations, too. Investing in testing another vaccine simply isn't a smart use of government money at this point.\nNow what\nThe Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":235,"commentSize":52,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}